IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes
03 Marzo 2023 - 8:07PM
via InvestorWire -- IBN, a multifaceted financial news and
publishing company for private and public entities, today announces
that Amir Reichman, CEO of biotechnology company BiondVax
Pharmaceuticals Ltd. (NASDAQ: BVXV), recently appeared on the
popular Test. Optimize. Scale., a podcast series featuring industry
leaders and pioneers sharing insights and experiences of growing
their businesses to scale.
The broadcast, hosted by Jason Fishman, SVP Digital Strategy for
Digital Niche Agency, is available for on-demand listening on Test.
Optimize. Scale.
To begin the interview, Reichman discussed his professional
journey leading up to joining BiondVax in 2021.
“My first encounter with entrepreneurship was when I graduated
with my bachelor’s degree. I was looking for an interesting project
to work on, and one of the pharmacology professors I worked with
introduced me to a very interesting patent for drug delivery across
the skin – transdermal delivery – for the treatment of Parkinson’s
disease,” Reichman said. “I suggested that I’d build the prototype
of this machine for my graduate project… and won first prize at the
university. With the prize money, I created a nice poster and sent
it to a conference in New York… My poster won first prize for young
scientists at the conference, and we got a $1 million grant from
the Michael J. Fox Foundation for Parkinson’s Research to develop
this invention.”
“I continued with the project throughout my master’s as the
first employee of a small company that we started called NeuroDerm.
This company grew quite rapidly, and we sold it in 2017 to
Mitsubishi Tanabe Pharma for $1.1 billion in cash. That was a very
nice start to my career as an entrepreneur… I didn’t stay with
NeuroDerm until the exit. I left in 2009 when I got a scholarship
to study at the Wharton Business School… Upon graduating from the
MBA, I worked in the United States with Novartis Vaccines and
Diagnostics in R&D, then with the global supply chain
organization as the Global Head of Value Chain Management… In 2015,
our company was acquired by GSK Vaccines in Belgium… where I
worked in global roles such as engineering and supply chain.”
“In 2020, we decided it was time to return to Israel… A week
later, a board member from BiondVax called me… They had a company
with a super team that knew how to develop drugs from zero to 100
and manage budget… They had massive labs and facilities… However,
they had $2.5 million in the bank and the IP [for its universal
influenza vaccine] had basically flopped [in a phase III trial] …
It was an excellent opportunity… to in-license a new technology to
the company. It becomes a new company in a very early stage, but
with a massive edge over others. The team is super experienced in
running trials… the capacity and capabilities are there. If we
raise enough money with a nice business plan, we can in-license a
technology and have a good start.”
Throughout the interview, Reichman continued to discuss his
journey with BiondVax, which is now developing a de-risked pipeline
of diversified and commercially viable products and platforms
beginning with an innovative nanosized antibody (NanoAb) pipeline
in licensed from the Max Planck Society.
Learn more by listening to the full interview at Test. Optimize.
Scale.
About BiondVax
BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company
focused on developing, manufacturing and commercializing innovative
immunotherapeutic products primarily for the treatment of
infectious and autoimmune diseases. Since its inception, the
company has executed eight clinical trials including a seven
country, 12,400 participant Phase 3 trial of its prior vaccine
candidate and has built a state-of-the-art manufacturing facility
for biopharmaceutical products. With highly experienced
pharmaceutical industry leadership, BiondVax is aiming to
develop a pipeline of diversified and commercially viable products
and platforms beginning with an innovative nanosized antibody
(NanoAb) pipeline. For more information, visit the company’s
website at www.BiondVax.com.
About IBN
IBN consists of financial brands introduced to the investment
public over the course of 17+ years. With IBN, we have amassed a
collective audience of millions of social media followers. These
distinctive investor brands aim to fulfill the unique needs of a
growing base of client-partners. IBN will continue to expand our
branded network of highly influential properties, leveraging the
knowledge and energy of specialized teams of experts to serve our
increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1)
access to a network of wire solutions via InvestorWire to reach all
target markets, industries and demographics in the most effective
manner possible; (2) article and editorial syndication to 5,000+
news outlets; (3) Press Release Enhancement to ensure maximum
impact; (4) full-scale distribution to a growing social media
audience; (5) a full array of corporate communications solutions;
and (6) total news coverage solutions.
For more information, please visit
https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or re-published:
http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBNLos Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Mag 2023 a Mag 2024